Carlos del Rio, M.D. (Chair), is the Hubert Professor and Chair of the Hubert Department of Global Health, Rollins School of Public Health of Emory University, and a professor of medicine at the Emory University School of Medicine. He is also principal investigator (PI) and co-director of the Emory Center for AIDS Research. Dr. del Rio is a native of Mexico, where he attended medical school at Universidad La Salle, graduating in 1983. He did his internal medicine and infectious disease residencies at Emory University. In 1989, he returned to Mexico, where he was executive director of the National AIDS Council of Mexico (the federal agency of the Mexican government responsible for AIDS policy throughout Mexico), from 1992 through 1996. In November 1996, he returned to Emory, where he has been involved in patient care, teaching, and research. Dr. del Rio was chief of the Emory Medical Service at Grady Memorial Hospital (2001–2009) and, since 2017, has been the interim executive associate dean for Emory at Grady. Dr. del Rio’s research focuses on the early diagnosis, access to care, engagement in care, compliance with antiretrovirals, and prevention of HIV infection. He has worked for more than a decade with hard-to-reach populations, including persons who use drugs, to improve outcomes of those infected with HIV and to prevent infection in those at risk. He is also interested in translating research findings into practice and policy. Dr. del Rio is conducting a study funded by the National Institute on Drug Abuse titled “Improving Physician Opioid Prescribing for HIV-Infected Patients with Chronic Pain.” He is co-PI of the National Institutes of Health–funded Emory–Centers for Disease Control and Prevention
(CDC) HIV Clinical Trials Unit, clinical site leader for the Adult AIDS Clinical Trials Group, and site PI for the HIV Prevention Trials Network of the National Institute of Allergy and Infectious Diseases. His international work includes collaborations in the countries of Georgia, Ethiopia, Kenya, Thailand, Vietnam, and Mexico. He has also worked on emerging infections, such as pandemic influenza, and was a member of the World Health Organization Influenza A (H1N1) Clinical Advisory Group and CDC Influenza A (H1N1) task force during the 2009 pandemic.
Julie A. Baldwin, Ph.D., is director of a new center on health equity research and a professor in the Department of Health Sciences in the College of Health and Human Services at Northern Arizona University. Prior to that, she was on the faculty at the University of South Florida (USF) College of Public Health in the Department of Community and Family Health. Before joining USF, she served as a tenured faculty member at Northern Arizona University, with a joint appointment in the Mel and Enid Zuckerman Arizona College of Public Health. She has worked for more than 28 years with tribal communities in northern Arizona to design culturally relevant health promotion programs for youth and their families.
Dr. Baldwin’s research over the years has focused on both infectious and chronic disease prevention targeting children, adolescents, and families. Cross-cutting themes that have characterized her work include using community-based participatory research approaches, working with underserved and/or marginalized populations, and addressing health disparities by developing and implementing culturally competent public health interventions. She has been principal investigator (PI) or co-PI of several federally funded projects from such agencies as the Centers for Disease Control and Prevention, National Institute of Mental Health, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institute on Minority Health and Health Disparities, the Robert Wood Johnson Foundation, and the Health Resources and Services Administration/Association for Multidisciplinary Education and Research in Substance Use and Addiction–Substance Abuse and Mental Health Services Administration/Center for Substance Abuse Treatment. For more than 28 years, Dr. Baldwin has had a consistent program of applied research addressing HIV/AIDS and substance use disorder prevention in youth, with a special emphasis on American Indian adolescents and their families. She continues to contribute significantly to this field of research today, as the co-director of the National Institute on Drug Abuse Research Education grants “Institute for Translational Research in Adolescent Behavioral Health” and “Intertribal Talking Circle for the Prevention of Substance Abuse in Native Youth.”
She earned her doctorate in behavioral sciences and health education in 1991 from the Johns Hopkins University School of Hygiene and Public Health. As an enrolled member of the Cherokee Nation of Oklahoma, she made a lifelong commitment to serving diverse communities and advocating for health promotion programs for children, adolescents, and families.
Edwin Chapman, M.D., is the chief medical officer of Medical Home Development Group, a multi-specialty, physician-led, physician-owned medical service organization headquartered in Washington, DC. Dr. Chapman has delivered high-quality care in DC for 40 years, specializing in internal medicine and addiction medicine. He currently collaborates with the Howard University Urban Health Initiative as an adjunct assistant professor in the Department of Behavioral Health and Psychiatry, investigating the complex mix of substance use, undertreated mental illness, infectious diseases (AIDS and hepatitis C), criminal behavior, and chronic diseases. Using an innovative “virtual office telemedicine design,” that initiative brought together the Departments of Behavioral Health and Psychiatry, Family and Community Medicine, Internal Medicine, and Pediatrics in a successful collaboration with the DC Department of Community Health addressing the needs of opioid-addicted index patients and their entire families.
Hannah Cooper, Sc.D., is the Rollins Chair in Substance Use Disorders. Dr. Cooper is a professor and vice chair in the Department of Behavioral Sciences and Health Education at Rollins, co-director of the Prevention Science Core at the Emory Center for AIDS Research, and director of Rollins’ Socio-Contextual Determinants of Health certificate program. Dr. Cooper’s research primarily focuses on social determinants of HIV-related outcomes, particularly among people who use drugs. She currently leads five National Institutes of Health–funded studies on these topics—including the CARE2HOPE project, which studies substance misuse and related harms among people who inject opioids in rural Kentucky. Her work has been cited in the National HIV/AIDS Strategy for the United States and published in numerous preeminent journals, including American Journal of Public Health, Journal of Urban Health, and Social Science & Medicine. Dr. Cooper received her bachelor’s degree from Yale, followed by her Sc.D. in health and social behavior from Harvard; she completed her postdoctoral fellowship in drug use and HIV at the National Development and Research Institutes. Since joining Rollins in 2008, Dr. Cooper has gained the respect of colleagues and collaborators across the university. She was recognized for her outstanding leadership qualities with the Emory Williams Teaching Award in 2015.
David Gustafson, Ph.D., directs the University of Wisconsin–Madison’s Center for Health Enhancement Systems Studies. His research interests focus on developing systems engineering tools to support sustainable individual and organizational improvement in substance use, cancer, and aging. NIATx grew to a network of more than 3,000 substance use treatment agencies and has conducted nationwide experiments to test the effectiveness of quality improvement models to enhance access to and retention in substance use treatment. His other implementation research interests focus on developing systems engineering tools to encourage individual and organizational change. His individual change research develops and tests computer systems (CHESS) to help people deal with serious illness. The substance use program—ACHESS—has been used by more than 6,000 patients. Randomized trials found that ACHESS reduced risky drinking and improved retention in treatment and abstinence. Other versions of CHESS have also improved outcomes in areas such as HIV, asthma, and breast, lung, and colon cancer. Dr. Gustafson and his colleagues have produced models to predict and explain implementation, sustainability, and diffusion of innovations and to measure quality of care and understand customer needs. He is an author of more than 300 reviewed publications, including 7 books. He is a member of the National Academy of Engineering and a fellow of the Association for Health Services Research, the American Medical Informatics Association, the W.K. Kellogg Foundation, and the Institute for Healthcare Improvement, which he co-founded and for which he served as board vice chair. He co-chaired the federal Science Panel on Interactive Communications in Health, was on several National Institutes of Health Study Sections, and is a member of the National Advisory Council of the Substance Abuse and Mental Health Services Administration. He serves on two National Academies committees.
Holly Hagan, Ph.D., is a professor at New York University College of Global Public Health and co-director of the National Institute on Drug Abuse P30 Center for Drug Use and HIV/HCV Research. She is trained as an infectious disease epidemiologist, with an emphasis on methods to study disease causation and control. Her research has addressed the etiology, epidemiology, natural history, prevention, and treatment of blood-borne and sexually transmitted infections among people who use drugs. Currently, she studies the epidemiology and response to the opioid and overdose epidemics, and she is the chair of the executive steering committee for the Rural Opioid Initiative funded by National Institutes of Health, Centers for Disease Control and Prevention (CDC), Substance Abuse and Mental Health Services Administration, and the Appalachian Regional Commission. Dr. Hagan is a member of the World Health Organization
Global Burden of Disease Study Diseases and Injuries Group, she served on the National Academies committee on the Prevention and Control of Viral Hepatitis in the United States, and she has been an advisor to the Department of Health and Human Services, CDC, and the Canadian Institutes of Health on national programs to detect, diagnose, and treat hepatitis C virus infections.
Robin P. Newhouse, Ph.D., R.N., FAAN, is the dean of the Indiana University (IU) School of Nursing and an IU distinguished professor. Her research focuses on health system interventions to improve care processes and patient outcomes. She has published extensively on health services improvement interventions, acute care quality issues, and evidence-based practice. Dr. Newhouse was appointed to the Methodology Committee of the Patient-Centered Outcomes Research Institute and currently is serving as the committee’s chair. She has been on multiple National Academies committees and is the immediate past chair of the AcademyHealth Board. Dr. Newhouse was inducted into the Sigma Theta Tau International Honor Society of Nursing Nurse Researcher Hall of Fame in 2014 and received the American Nurses Credentialing Center President’s Award in 2015. In 2017, Dr. Newhouse was elected as a member of the National Academy of Medicine. Dr. Newhouse currently is serving as the lead investigator for IU’s Grand Challenge: Responding to the Addictions Crisis, which is a $50 million initiative in partnership with the state and major health care systems in Indiana to reduce substance use disorders, the number of people who die because of an opioid overdose, and the number of babies born exposed to substances that result in neonatal abstinence syndrome. Dr. Newhouse is also principal investigator of two current studies. The first study tests the effectiveness and implementation of a Screening Brief Intervention Referral to Treatment toolkit to identify people who use substances and get them the help that they need across settings that range from critical access hospitals to academic health centers. The second study assesses the workforce available to address the substance use crisis across the state and will create a Web-based resource for clinicians to use to refer people who use substances to treatment when indicated.
Josiah “Jody” D. Rich, M.D., M.P.H., is a professor of medicine and epidemiology at Brown University and a practicing infectious disease and addiction specialist providing care to patients at the Miriam Hospital and the Rhode Island Department of Corrections since 1994. He has published close to 200 peer-reviewed publications, predominantly in the overlap between infectious diseases (IDs), substance use, and incarceration. He is the director and co-founder of the Center for Prisoner Health and Human Rights at the Miriam Hospital (www.prisonerhealth.org) and
co-founder of the nationwide Centers for AIDS Research Collaboration on HIV in Corrections initiative. Dr. Rich has advocated for public health policy changes to improve the health of people with substance use disorders, including improving legal access to sterile syringes and increasing drug treatment for incarcerated and formerly incarcerated populations. He has had continuous National Institutes of Health research funding for more than two decades. His primary areas of interest and expertise are in the overlap between IDs and illicit substance use, the treatment and prevention of HIV infection, and the care and prevention of disease in addicted and incarcerated individuals. More recently, he has focused on addressing the opioid overdose epidemic. He has testified in Congress multiple times and served as an expert advisor to Rhode Island Governor Gina Raimondo’s Overdose Prevention and Intervention Task Force since its inception in 2015.
Sandra Springer, M.D., is an associate professor of medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. She is also the director of the Infectious Disease Clinic at the Newington site and an attending infectious disease physician at the West Haven site of the VA Connecticut Healthcare System. She is board certified in internal medicine, infectious diseases, and addiction medicine. She has significant clinical and research experience with use of medications for the treatment of opioid and alcohol use disorders among persons living with HIV, in the criminal justice system, and persons in the community in both inpatient and outpatient settings. She developed the first protocol to use buprenorphine to improve HIV treatment outcomes as relapse prevention for released prisoners with opioid use disorder (OUD) and HIV. She has conducted randomized controlled trials and evaluated the impact of extended-release naltrexone (XR-NTX), approved for treatment of both alcohol and OUD, as a principal investigator (PI) for a National Institute on Alcohol Abuse and Alcoholism–funded study among prisoners with HIV and alcohol use disorders and a PI for a National Institute on Drug Abuse (NIDA)-funded study among prisoners and jail detainees with OUD and HIV. Both studies found that XR-NTX improved HIV viral suppression 6 months after release to the community. She currently is co-leading two NIDA-funded studies evaluating the impact of medications for opioid use disorder (methadone and buprenorphine) on immunobiological outcomes among persons with OUD with and without HIV and of buprenorphine, methadone, and XR-NTX on HIV latency and persistence among persons with OUD and HIV. She was a working group member of the National Academies’ historic meeting calling for action to integrate OUD and infectious disease treatment and is a current member of the American Society of Addiction Medicine’s
National Practice Guideline Expert Panel for Medication Treatment for OUD and the Infectious Diseases Society of America and HIV Medical Association Working Group on Infectious Disease Issues in the Opioid Epidemic. She has presented her work at numerous national and international conferences and published more than 100 manuscripts, book chapters, and abstracts regarding the subject of HIV, the criminal justice system, and substance use disorders.
David L. Thomas, M.D., is the Stanhope Bayne-Jones Professor of Medicine and chief of the division of Infectious Diseases at the Johns Hopkins University School of Medicine. His nearly 30-year career has been based in East Baltimore, Maryland, where, through his research, clinical care, and administrative roles, he has accumulated knowledge of the intersection of the opioid epidemic and infectious diseases (IDs). His particular area of focus has been viral hepatitis and HIV. His lab has produced some of the seminal findings regarding hepatitis viruses among persons who inject drugs and the influence of HIV on those outcomes. He also has clinical expertise caring for ID complications of opioid use through his role as an ID consultant at the Johns Hopkins Hospital. He has served on multiple panels, including for the National Academy of Medicine, National Institutes of Health, Centers for Disease Control and Prevention, and the related professional societies (American Association for the Study of Liver Diseases [AASLD] and Infectious Diseases Society of America [IDSA]), as an associate editor for leading journals such as Clinical Infectious Diseases and Journal of Clinical Investigation, and was recognized by IDSA with its Citation Award for his work pioneering the AASLD/IDSA hepatitis C guidance.
This page intentionally left blank.